The Pharmaceutical & Healthcare Team

The Pharmaceutical & Healthcare team prides itself on providing superior guidance to our international clients. Our clients can be reassured that each piece of advice given to them, has been dissected through a series of scientists and toxicologists that can only be provided by the size of our team. To become better acquainted with our team, please select a name from the list of our designated senior scientists. We have only listed senior staff on the website, additional members of the team have bios that are available upon request.

Management:

• Lindsay N. Donald, DABT, Vice President, Pharmaceutical & Healthcare Group
• Anna Metcalfe, RAC, Vice President, Regulatory Affairs, Pharmaceutical & Healthcare Group 
• Valentia Lee-Brotherton, Ph.D., Director, Toxicology, Pharmaceutical & Healthcare Group

Toxicology and Product Development:

• Lois A. Haighton, B.Sc., DABT, ERT
• Barry Lynch, B.Sc., DABT
• Jeffrey W. Card, Ph.D. 
• Joanne Wan, Ph.D., DABT 
   

Anna Metcalfe, RAC
Vice President, Regulatory Affairs

Ms. Metcalfe, the Vice President of Regulatory Affairs within the Pharmaceutical & Healthcare Group, oversees regulatory staff in the planning, organization, and co-ordination of nonclinical, clinical, and regulatory submission activities. Her primary responsibility is to provide strategic and operational regulatory expertise and leadership necessary to advance the nonclinical and clinical development of drug products from Phase I to Phase III worldwide, for many clients.

With over 25 years experience in various therapeutic areas in International Regulatory Affairs, she has developed skills in Clinical Research, Project Management, Drug Development, Medical Information and Medical Research. Ms. Metcalfe has successfully acted as Project Leader for the development of a number of drug candidates from the nonclinical stage to marketing authorizations in the US, Canada, and EU.

Ms. Metcalfe received an Honours Bachelor of Science degree with a specialty in Pharmacology from the University College London, England and has several publications in the area of regulatory and clinical affairs.

Valentia Lee-Brotherton, Ph.D.
Director

Since joining the Pharmaceutical & Healthcare Group, Dr. Lee-Brotherton has been involved in the design, implementation, and management of nonclinical testing programs. She has tailored detailed product development strategies for new drugs and biopharmaceuticals for a wide range of products, including drugs with specialized routes of administration, small molecules, proteins and peptides, in a variety of indications, such as cancer, pain, and inflammation. Dr. Lee-Brotherton has been involved in tasks ranging from lead candidate selection to preparation and review of regulatory submissions for a large number of projects. She has specialized in numerous aspects of general toxicology, involving risk assessments and independent third-party reviews of toxicology and safety data.

Dr. Lee-Brotherton’s 11 years of research background in toxicology and chemical carcinogenesis, knowledge of chemical carcinogens, drugs, toxic agents, and biotechnologicals, and her extensive experience with both in vitro and in vivo studies in drug metabolism and mechanisms of toxicity, toxicology, and tumorigenesis, continues to serve our clients well in her capacity as a Senior Project Manager and Director. Dr. Lee-Brotherton has maintained projects and relationships with many pharmaceutical and biotechnology clients that have spanned over 6 years.

Dr. Lee-Brotherton obtained her B.Sc. and Ph.D. from the University of Toronto, and then completed 3 years of training as a post-doctoral fellow at the London Regional Cancer Centre in London, Ontario, Canada. Dr. Lee-Brotherton is a member of the American Association of Cancer Research and has authored and co-authored a number of publications in the fields of toxicology and carcinogenesis.

Jeffrey W. Card, Ph.D.
Senior Program Manager, Toxicology

Since joining the Pharmaceutical & Healthcare Group in 2007, Dr. Card has worked closely with clients in the pharmaceutical and biotechnology industries to design and implement nonclinical toxicology programs, address excipient and drug contaminant issues, conduct risk assessments, and prepare regulatory submissions. Dr. Card also is the head of the Intertek Cantox nanotechnology team, serving as a vital resource and manager of projects related to nanotechnology and nanotoxicology.

After receiving his Ph.D. in Pharmacology and Toxicology from Queen’s University, Dr. Card spent 4 years as a postdoctoral fellow at the National Institute of Environmental Health Sciences in Research Triangle Park, NC. He has over 10 years of research experience in academic and government laboratories, has authored over 20 peer-reviewed articles in the fields of toxicology, physiology, carcinogenesis, and nanotechnology and has given presentations at local, national, and international scientific meetings. His academic and research excellence have been recognized in the form of travel, scholarship, and fellowship awards from the Davies Charitable Foundation, the Canadian Institutes of Health Research, the Society of Toxicology, the American Lung Association of North Carolina, and the National Institutes of Health. Dr. Card is a member of the Society of Toxicology, the Society of Toxicology of Canada, and the American Association for the Advancement of Science.

Joanne Wan, Ph.D., DABT
Senior Program Manager, Toxicology

Since joining Intertek Cantox in 2007, Dr. Wan has helped clients address specific toxicology and reproductive and developmental toxicology issues. She assists clients with the design and implementation of nonclinical toxicology programs in areas such as oncology drugs, antiinfectives, and dermal products. Dr. Wan also conducts critical reviews of data and reports with a view towards submission writing, including Investigator’s Brochures and Nonclinical Summaries. Her involvement with nonclinical development programs also includes nonclinical Contract Research Organization (CRO) site selection visits, and on-site monitoring of nonclinical studies for scientific integrity and adherence to the principles of Good Laboratory Practice.

In addition to these activities, Dr. Wan also conducts toxicology safety and risk assessments for product impurities, excipients, extractables and leachables and assists clients with efficacy claims for cosmetic, natural health products, and dietary supplements.

Her research has been recognized in the form of scholarship awards from the Canadian Institutes of Health Research and the Canadian Cancer Society Research Institutes’ Programme of Research in Environmental Etiology of Cancer. She is a member of the Society of Toxicology.